Major Study Finds Most Antidepressants Safe During Pregnancy

Largest Study Yet Challenges Common Pregnancy Fears

Pregnant women who need antidepressants can breathe easier after researchers published the most comprehensive evidence to date showing these medications don't increase autism or ADHD risk in children. The massive analysis examined 37 studies covering more than 600,000 pregnancies with antidepressant use and nearly 25 million pregnancies without , making it the largest investigation of its kind.

"We know many parents-to-be worry about the potential impact of taking medication during pregnancy; our study provides reassuring evidence that commonly used antidepressants do not increase the risk of neurodevelopmental disorders such as autism and ADHD in children," said study author Dr. Wing-Chung Chang of the University of Hong Kong. The research, published in The Lancet Psychiatry, addresses growing concerns that have made many pregnant women hesitant to continue necessary mental health treatment.

The timing couldn't be more crucial. Antidepressants are the main treatment for depression, which affects more than 10% of pregnant women worldwide . Yet fears about potential harm to developing babies have left many women and their doctors in difficult positions, weighing the risks of untreated depression against perceived medication dangers.

The Real Story Behind Alarming Statistics

The study initially appeared to confirm parents' worst fears. Before controlling for other factors, researchers found antidepressant use during pregnancy was linked with a 35% higher risk of ADHD and a 69% higher risk of autism . These numbers would be terrifying for any expectant parent taking these medications.

But here's where the story takes a dramatic turn. When researchers adjusted for maternal mental health and other confounding factors, these associations largely disappeared or became non-significant . The apparent risks weren't caused by the medications themselves but by underlying family factors, including genetics and the severity of mental health conditions that required treatment.

Perhaps the most telling evidence came from an unexpected source: fathers. Children whose fathers used antidepressants during the mother's pregnancy also showed higher rates of autism and ADHD, even though paternal medication obviously cannot reach the baby in the womb . "A father's medication obviously cannot reach the baby in the womb, so this pattern is very hard to explain by anything other than shared family traits," researchers noted.

What This Means for Treatment Decisions

The findings provide crucial clarity for the most commonly prescribed antidepressants, particularly SSRIs (selective serotonin reuptake inhibitors). "This large meta-analysis provides further evidence that selective serotonin reuptake inhibitors exposure during pregnancy is not associated with autism or ADHD in exposed children," noted Dr. Jennifer Payne, speaking to Psychiatric Times.

However, the study did identify one notable exception. When other factors were considered, only two older antidepressants—amitriptyline and nortriptyline—remained linked with higher ADHD risk . These drugs are typically reserved for patients whose depression hasn't responded to other treatments, suggesting women treated with them may have had more complicated mental health conditions .

For women currently taking these older medications, the research doesn't provide a clear answer about causation. "It is worthwhile for pregnant individuals on these older medications or considering starting them to discuss the potential risks and benefits with their clinicians," researchers advised.

Balancing Risks in Real-World Decisions

The study's implications extend far beyond statistics. "While all medications carry risks, so too does stopping antidepressants during pregnancy due to an increased risk of relapse," Dr. Chang emphasized. Untreated depression during pregnancy carries its own serious risks, including poor prenatal care, substance use, and postpartum complications.

The research comes at a particularly relevant time, as concerns have been amplified by July 2025 FDA expert panel discussions about possibly strengthening warnings on SSRIs in pregnancy, highlighting potential risks such as autism, miscarriage, and birth defects . These discussions have created additional anxiety for pregnant women and their healthcare providers.

Rather than making blanket recommendations, the study empowers individualized decision-making. The findings, "together with a growing body of rigorous science on the topic of antidepressant use during pregnancy, offer meaningful reassurance about safety of contemporary antidepressants," giving women and their doctors better information to weigh treatment options. The research suggests that for most women, the benefits of continuing antidepressant treatment likely outweigh the risks, fundamentally shifting how we think about mental health care during pregnancy.